Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Alex Ganetsky, PharmD, BCOP, Jennifer H Han, MD MSCE, Mitchell E Hughes, PharmD, Daria V. Babushok, MD PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth Hexner, MD, Alison Wakoff Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, Craig W. Freyer, PharmD, BCOP, Cheryl Gilmar, MT, David L Porter, MD

Blood (2016) 128 (22): 2225.

https://doi.org/10.1182/blood.V128.22.2225.2225

Published: 2016

Journal Articles

Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

Andrew S. Artz, MD MS, Brent R. Logan, PhD, Xiaochun Zhu, MS, Görgün Akpek, MD MHS, Rodrigo Martino, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hillard M. Lazarus, MD, Mark R. Litzow, MD, Alison Wakoff Loren, MD MS, Navneet S. Majhail, MD MS, Richard T. Maziarz, MD, Philip L. McCarthy, MD, Uday R. Popat, MD, Wael Saber, MD MS, Stephen R. Spellman, MBS, Olle Ringdén, MDPhD, Kenneth R. Cooke, MD, Marcelo C. Pasquini, MD MS

Blood (2014) 124 (21): 422.

https://doi.org/10.1182/blood.V124.21.422.422

Published: 2014

Journal Articles

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Jennifer McQuade, MD, Tahamtan Ahmadi, MD, PhD, David Porter, Noelle Frey, Alison Wakoff Loren, MD, MS, Steven C. Goldstein, MD, Jakub Svoboda, MD, Edward Stadtmauer, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2010) 116 (21): 3570.

https://doi.org/10.1182/blood.V116.21.3570.3570

Published: 2010

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, MD, PhD, Melissa Potuzak, BS, Anthony Mato, MD, Alison Wakoff Loren, MD, MS, David Porter, MD, Edward A. Stadtmauer, MD, Steven Goldstein, MD, Alexander Perl, MD, Cezary Swider, BS, Adam Bagg, MD, Emile Youssef, MD, PhD, Selina Luger, MD

Blood (2008) 112 (11): 4040.

https://doi.org/10.1182/blood.V112.11.4040.4040

Published: 2008

NARROW

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only